By Product
- Reagent
- Media & Sera
- Stains & Dyes
- Fixatives
- Buffers
- Solvents
- Enzymes
- Probes
- Other Reagents
- Antibodies
- By Type
- Primary Antibodies
- Secondary Antibodies
- By Form
- Monoclonal
- Polyclonal
- Recombinant
- By Source
- Mice
- Rabbits
- Other Sources
- By Research Area
- Oncology
- Infectious Diseases
- Immunology
- Neurobiology
- Stem Cells
- Other Research Areas
By Technology
- Western Blotting
- Flow Cytometry
- Enzyme-linked immunosorbent assay (ELISA)
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Other Technologies
By Application
- Proteomics
- Drug Development
- Genomics
By End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
The market is categorised into product, technology, application, end user and region. The product segment is fragmented into reagents and antibodies. The reagents segment is predicted to hold the largest research antibodies and reagents market share owing to the increased usage of reagents in multiple research techniques and assays, rising utilization of reagents or understanding the molecular basis of a disease. The technology segment is divided into western blot, immunofluorescence, immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA). The western blot segment is anticipated to lead the market during the forecast period and this is primarily due to increased research fund for discovering biomarkers, cell-based and antibody research and high insistence for efficient testing kits for detecting agents that cause the viral disease.
The application segment is categorised into proteomics, drug development and genomics. The proteomics segment is predicted to dominate the market and this ca n be credited to the rise in the research for anti-cancer drug candidates, the increased necessity for developing effective drugs and assessment of the patient response and drug efficacy. The end user segment is fragmented into pharmaceutical and biotechnology companies, academic and research institutes and contract research organizations. The pharmaceutical and biotechnology companies are predicted to lead the market owing to rise in the investments for research activities, rising acceptance of research reagents and antibodies for proteomics research programs and rising insistence for efficient personalised medicine.
The North America region is anticipated to dominate the market owing to the presence of key market players in the region. The Europe region follows the growth rate of North America during the forecast period. As per the European Union, the Horizon 2020 program launched by the government in 2016 invested over USD 85 billion, of which over 9% was used by the healthcare sector. This program was initiated for supporting and developing personalised medicines.